美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Orexigen Therapeutics

0.2229

0.0000

成交量：- -

成交額：- -

市值：420.99萬

市盈率：-0.02

高：0.2229

開：0.2229

低：0.2229

收：0.2229

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Orexigen Therapeutics

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.orexigen.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Orexigen Therapeutics, Inc.於2002年9月在特拉華成立。Orexigen治療股份有限公司是一家生物製藥公司，專註於發展治療肥胖的候選醫藥產品。公司的主導產品有針對肥胖者的已完成三期臨床試驗的納曲酮和已完成二期臨床試驗的empati。納曲酮是兩個行之有效的藥物的組合，包括安非他酮，納曲酮。安非他酮是一種廣泛應用的抗抑鬱藥和戒煙藥物；納曲酮用於酒精和阿片成癮治療。Empatic的組合是安非他酮和唑尼沙胺，唑尼沙胺立即釋放製劑在美國被批准用於部分癲癇發作的輔助治療。每個候選產品在商業化之前都將獲得監管機構的批准。公司在努力的向監管機構證明這些組合的療效和安全性，以獲得批准。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/OREX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OREX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OREX\",,,,,undefined,":{"symbol":"OREX","market":"US","secType":"STK","nameCN":"Orexigen Therapeutics","latestPrice":0.2229,"timestamp":1522785600000,"preClose":0.2229,"halted":4,"volume":0,"delay":0,"floatShares":9677447,"shares":18887033,"eps":-9.700626,"marketStatus":"退市","change":0,"latestTime":"04-03 16:00:00 EDT","open":0.2229,"high":0.2229,"low":0.2229,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-9.700626,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1747987200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1177560000000,"exchange":"NASDAQ","adjPreClose":0.2229,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OREX\",,,,,undefined,":{"symbol":"OREX","floatShares":9677447,"roa":"--","roe":"--","lyrEps":0,"shares":18887033,"dividePrice":0,"high":0.2229,"amplitude":0,"preClose":0.2229,"low":0.2229,"week52Low":0.1708,"pbRate":"-0.07","week52High":3.805,"institutionHeld":0.9018,"latestPrice":0.2229,"eps":-9.700626,"divideRate":0,"volume":0,"delay":0,"ttmEps":-9.700626,"open":0.2229},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.orexigen.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0125},{"period":"1month","weight":0.1059},{"period":"3month","weight":-0.0281},{"period":"6month","weight":-0.0209},{"period":"1year","weight":0.1005},{"period":"ytd","weight":-0.0051}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Orexigen Therapeutics, Inc.於2002年9月在特拉華成立。Orexigen治療股份有限公司是一家生物製藥公司，專註於發展治療肥胖的候選醫藥產品。公司的主導產品有針對肥胖者的已完成三期臨床試驗的納曲酮和已完成二期臨床試驗的empati。納曲酮是兩個行之有效的藥物的組合，包括安非他酮，納曲酮。安非他酮是一種廣泛應用的抗抑鬱藥和戒煙藥物；納曲酮用於酒精和阿片成癮治療。Empatic的組合是安非他酮和唑尼沙胺，唑尼沙胺立即釋放製劑在美國被批准用於部分癲癇發作的輔助治療。每個候選產品在商業化之前都將獲得監管機構的批准。公司在努力的向監管機構證明這些組合的療效和安全性，以獲得批准。","exchange":"NASDAQ","name":"Orexigen Therapeutics","nameEN":"Orexigen Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OREX\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OREX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-11-13","symbol":"OREX","fiscalQuarterEnding":"2017/09","expectedEps":-2.13,"name":null,"time":"盤後","type":"earning","dateTimestamp":1510549200000,"reportTimeType":"post","actualEps":-1.35},{"market":"US","date":"2017-08-08","symbol":"OREX","fiscalQuarterEnding":"2017/06","expectedEps":-2.4,"name":null,"time":"盤後","type":"earning","dateTimestamp":1502164800000,"reportTimeType":"post","actualEps":-1.82},{"market":"US","date":"2017-05-09","symbol":"OREX","fiscalQuarterEnding":"2017/03","expectedEps":-2.6,"name":null,"time":"盤後","type":"earning","dateTimestamp":1494302400000,"reportTimeType":"post","actualEps":-4.67},{"market":"US","date":"2017-03-28","symbol":"OREX","fiscalQuarterEnding":"2016/12","expectedEps":-0.54,"name":null,"time":"盤前","type":"earning","dateTimestamp":1490673600000,"reportTimeType":"pre","actualEps":-2.67},{"market":"US","date":"2016-11-03","symbol":"OREX","fiscalQuarterEnding":"2016/09","expectedEps":-2.13,"name":null,"time":"盤後","type":"earning","dateTimestamp":1478145600000,"reportTimeType":"post","actualEps":-1.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OREX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OREX\",market:\"US\",delay:false,,,undefined,":{}}}